To target the IGF2BP1 signaling pathway directly, we utilized the recently published small molecule inhibitor BTYNB which interferes with IGF2BP1 binding to its target mRNAs, such as MYC, thereby impairing tumor cell proliferation [51]. The gene discussed is MYC; the disease is neoplasm.